There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rezolute (RZLT – Research Report) and KalVista Pharmaceuticals (KALV – Research Report) with bullish sentiments.
Rezolute (RZLT)
In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Rezolute, with a price target of $14.00. The company’s shares closed last Tuesday at $1.09.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of
Currently, the analyst consensus on Rezolute is a Moderate Buy with an average price target of $10.50, implying a 782.4% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $7.00 price target.
See today’s best-performing stocks on TipRanks >>
KalVista Pharmaceuticals (KALV)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on KalVista Pharmaceuticals, with a price target of $24.00. The company’s shares closed last Tuesday at $14.85.
According to TipRanks.com, Fein is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for KalVista Pharmaceuticals with a $30.75 average price target, representing a 94.1% upside. In a report issued on February 1, Leerink Partners also maintained a Buy rating on the stock with a $20.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RZLT:
- Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
- Is RZLT a Buy, Before Earnings?
- Rezolute Receives Innovation Passport, Appoints New CFO
- Rezolute appoints Evans as Chief Financial Officer
- Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
